CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior / VÃrios distÃrbios neurolÃgicos foram observados em pacientes com doenÃa inflamatÃria intestinal (DII), porÃm sua prevalÃncia exata à desconhecida. Estudamos prospectivamente a incidÃncia e a prevalÃncia das manifestaÃÃes neurolÃgicas em uma coorte de 82 pacientes com DII (protocolo 1) e a presenÃa e gravidade de tremor em pacientes com DII e voluntÃrios sadios (Protocolo 2). Os pacientes do protocolo 1 foram avaliados no ambulatÃrio de DII do Hospital Walter CantÃdio por um perÃodo de pelo menos 1 ano, realizando avaliaÃÃes neurolÃgicas completas periÃdicas. O segundo protocolo consistiu na quantificaÃÃo de tremor em espirais de Arquimedes realizadas por pacientes com doenÃa de Crohn (DC, N=31), retocolite ulcerativa (RCU, N=63) e voluntÃrios sadios (N=41) por um neurologista especializado em distÃrbios de movimento (Dr. Elan Louis, Columbia University, Nova Iorque). Polineuropatia de fibras grossas sensitivas ou sensitivo-motoras foi observada em 16,1% dos pacientes com DC e 19,6% dos pacientes com RCU, sendo usualmente leve, predominantemente simÃtrica, distal e axonal. SÃndrome do tÃnel do carpo foi observada comumente em mulheres com RCU. Sintomas sensitivos sem anormalidades eletromiogrÃficas, sugestivos de neuropatia de pequenas fibras ou mielopatia subclÃnica, foram observados em 29% dos pacientes com DC e 11,8% com RCU. ApÃs excluir outros fatores etiolÃgicos ou contributÃrios para polineuropatia, 13,4% dos pacientes com doenÃa inflamatÃria intestinal apresentaram polineuropatia de fibras grossas ou fibras finas (7,3% com polineuropatia de fibras grossas sensitivo-motoras). CefalÃia nÃo debilitante foi a queixa neurolÃgica mais comum, 3 pacientes apresentaram acidente vascular cerebral isquÃmico, 5 epilepsia e 1 corÃia transitÃria. Pacientes com DII apresentaram menor quantidade de tremor que os voluntÃrios sadios devido ao menor uso de cafeÃna. Nos pacientes com DC, houve correlaÃÃo significativa entre a nota do tremor, uso de medicaÃÃes com aÃÃo sobre o sistema nervoso central, uso e quantidade de cafeÃna e presenÃa de doenÃas neurolÃgicas. Em pacientes com RCU, sà houve correlaÃÃo significativa entre a nota do tremor e idade ou uso/quantidade de cafeÃna ingerida. Em resumo, pacientes com RCU e DC apresentam uma vasta gama de manifestaÃÃes neurolÃgicas que sÃo com freqÃÃncia clinicamente negligenciadas / Several neurological disorders have been described in inflammatory bowel disease (IBD) patients, but their exact prevalence is unknown. We prospectively studied the prevalence and incidence of neurological disorders in a cohort of 82 patients with IBD (protocol 1) and the presence and severity of tremor in patients with IBD or healthy volunteers (Protocol 2). Patients from protocol 1 were evaluated at the IBD Clinic from the Hospital Walter CantÃdio for at least one year, with complete periodic neurological evaluations. The second protocol consisted in quantifying the amount of tremor in Archimedes spirals from patients with CrohnÂs disease (CD, N=31), ulcerative colitis (UC, N=63) and healthy volunteers (N=41) by a neurologist specialized in movement disorders (Dr. Elan Louis, Columbia University, New York City). Sensory or sensorimotor large-fiber polyneuropathy was observed in 16.1% of the patients with CD and 19.6% of the patients with UC. Neuropathy was usually mild, predominantly distal, symmetric, and axonal. Carpal tunnel syndrome was more commonly observed in women with UC. Sensory complaints without electrodiagnostic (EMG) abnormalities suggestive of small fiber neuropathy or subclinical myelopathy were observed in 29% of the patients with CD and 11.8% of the patients with UC. After excluding other etiological or contributory factors for the development of neuropathy, still 13.4% of the IBD patients had large or small fiber neuropathy (7.3% had large-fiber polyneuropathy). Non-debilitating headache was the most common neurological complaint, 3 patients had strokes, 5 were diagnosed with epilepsy and one had transient chorea. Patients with IBD had lower scores of tremor in the Archimedes spiral assessment due to decreased caffeine intake. In patients with CD, there was a significant correlation between tremor grade, use of medications with effect on the central nervous system, use and amount of caffeine intake and presence of other neurological conditions. In patients with UC, there was only a significant correlation between tremor grade, age and use and the amount of caffeine intake prior to the evaluation. In summary, patients with CD and UC exhibit a wide range of neurological manifestations that are frequently neglected clinically

Submitted by Geandra Rodrigues (geandrar@gmail.com) on 2018-07-04T14:43:46Z No. of bitstreams: 1 alinecorrearibeiro.pdf: 2333411 bytes, checksum: 7c0df6693f47a6872d99460a06bc865b (MD5) / Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2018-07-06T14:24:16Z (GMT) No. of bitstreams: 1 alinecorrearibeiro.pdf: 2333411 bytes, checksum: 7c0df6693f47a6872d99460a06bc865b (MD5) / Made available in DSpace on 2018-07-06T14:24:16Z (GMT). No. of bitstreams: 1 alinecorrearibeiro.pdf: 2333411 bytes, checksum: 7c0df6693f47a6872d99460a06bc865b (MD5) Previous issue date: 2017-08-29 / Devido à importância que o sistema imune desempenha na doença de Crohn (DC), as tiopurinas são os imunomoduladores mais indicados na terapia. Entretanto, as tiopurinas, como a Azatioprina (AZA) e seus metabólitos intraeritrocitários, levam a uma série de reações adversas ou falha terapêutica, podendo ocasionar em não adesão ou abandono da terapia. A conversão da AZA para os nucleotídeos ativos de 6-tioguanina (6-TGN) é necessária para a eficácia clínica, entretanto, outro metabólito, a 6-metilmercaptopurina (6-MMP), é formado através de uma via concorrente pela tiopurina metil transferase e está relacionado à hepatotoxicidade. Devido à ampla variabilidade interindividual da tiopurina metil transferase e a uma faixa terapêutica estreita, torna-se importante a realização do monitoramento terapêutico do metabólito ativo 6-TGN e da 6-MMP. Neste trabalho, um método cromatográfico (CLAE/HPLC-UV) foi desenvolvido e validado para a quantificação dos metabólitos nos eritrócitos, envolvendo um procedimento de tratamento simples baseado na desproteinização por ácido perclórico seguido de hidrólise ácida e aquecimento para a conversão dos metabólitos em suas respectivas bases livres. A cromatografia foi realizada em coluna C18 (250 x 4,6 mm, 5 μm). A fase móvel consistiu em mistura de solução tampão fosfato de potássio (0,02 mol/L, pH = 3), acetonitrila e metanol, eluição por gradiente, num fluxo de 1,0 mL/minuto, com detecção de UV em 291 ηm e 342 ηm. Os tempos de retenção foram de 6,2 min (6-TGN); 23,1 min (6-MMP) e 24,7 min (cafeína: padrão interno). A resposta do detector foi linear na concentração de 0,89-29,91 μmol/L (r=0,999) para 6-TGN e entre 0,90-30,08 μmol/L (r=0,999) para 6-MMP. Os limites de detecção foram de 0,29 μmol/L e 0,30 μmol/L e os limites de quantificação foram de 0,89 μmol/L e 0,90 μmol/L, para 6-TGN e 6-MMP respectivamente. As médias das recuperações de 87,9% para 6-TGN e 91,9% para 6-MMP. Os CV da repetibilidade, de 5,48 e 10,48% (intradia) e 9,23 e 10,48% (interdia), enquanto os EPR da reprodutibilidade de 11,36 e 9,85% (intradia) e 10,48 e 7,32% (interdia) para 6-TGN e 6-MMP, respectivamente. As concentrações de 6-TGN e 6-MMP foram determinadas para todos os pacientes do estudo e os resultados encontrados variaram de 4,51 a 1515,27 ρmol/8 x 10⁸ eritrócitos para a 6-TGN e de 169,98 a 53951,53 ρmol/8 x 10⁸ eritrócitos para a 6-MMP. Observou-se uma correlação entre os pacientes em terapia combinada AZA e alopurinol e a diminuição da dosagem de AZA, consequentemente a diminuição significativa dos níveis de 6-MMP (2030,71 ρmol/8 x 10⁸ eritrócitos) em comparação com o grupo de pacientes sob monoterapia (9098,43 ρmol/8 x 10⁸ eritrócitos). Um outro achado foi a diminuição estatisticamente significativa da transaminase TGO/AST (25,03 + 18,62 U/L) no grupo de pacientes que apresentavam a doença em atividade, com os níveis de 6-TGN a 540,51 ρmol/8 x 10⁸ eritrócitos e de 6-MMP a 7952,32 ρmol/8 x 10⁸ eritrócitos, semelhante a relatos anteriores da literatura. O método proposto de quantificação por CLAE-UV mostrou-se preciso, exato e reprodutível, podendo ser utilizado como uma importante ferramenta na rotina de monitorização terapêutica de pacientes com DC, permitindo a individualização da dose, o acompanhamento dos efeitos adversos relacionados com a terapia farmacológica, o monitoramento da adesão ao tratamento e a avaliação da evolução clínica do paciente. / The conversion of azathioprine (AZA) to active nucleotides of 6-thioguanine (6-TGN) is essential for clinical efficacy in Crohn's disease. However, other metabolite, 6-methylmercaptopurine (6-MMP), which is formed through a competitive pathway for thiopurine methyltransferase (TPMT), is related to hepatotoxicity of this drug. Due to the wide interindividual variability of TPMT and a narrow therapeutic range it is important to accomplish the therapeutic monitoring of active metabolite 6-TGN and 6-MMP, which is an unusual procedure in Brazil. In this study, a HPLC-UV method for simultaneous quantification of these metabolites was developed, validated and applied in 37 Crohn's disease patients. The chromatographic process was performed on C18 column (250 x 4.6 mm, 5 μm i.d.), mobile phase consisted of potassium phosphate buffer (0.02 mol/L, pH = 3), acetonitrile and methanol, flow rate at 1.0 ml/min and UV detection at 291 ηm and 342 ηm. Retention times were 6.2 min (6-TGN); 23.1 min (6-MMP) and 24.7 min (caffeine: internal standard). The detector response was linear at 0.89-29.91 μmol/L (r=0.999) for 6-TGN and 0.90-30.08 μmol/L (r=0.999) for 6-MMP. Limits of detection were 0.29 μmol/L and 0.30 μmol/L, while the quantification limits were 0.89 μmol/L and 0.90 μmol/L, for 6-TGN and 6-MMP respectively. Precision, accuracy and recovery, were according FDA and ANVISA guidelines. The concentrations of 6-TGN and 6-MMP were determined in patients’ blood and the results found ranged from 4.51 to 1515 ρmol/8 x 10⁸ erythrocytes for 6-TGN and from 169.98 to 53.951 ρmol/8 x 10⁸ erythrocytes for 6-MMP. It was observed a reduction of levels of 6-MMP in patients using AZA + allopurinol therapy (2030.7 ρmol/8 x 10⁸ erythrocytes) when compared with patients undergoing monotherapy (9098.43 ρmol/8 x 10⁸ erythrocytes). Another finding was the correlation between the decrease in GOT transaminase in the group of patients who had the active disease with the increase in the 6-TGN levels, similar to previous reports in the literature. These results indicate that the method developed was reliable, accurate and reproducible, and can be used as an important tool in the routine monitoring of patients with Crohn's disease, allowing the individualization of the dose, the monitoring of the adverse effects related to the pharmacological therapy, monitoring the adherence to the treatment and the evaluation of the clinical evolution of these patients.

Orientador: Maria Marluce dos Santos Vilela / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-23T14:15:40Z (GMT). No. of bitstreams: 1 Machado_JuliaFigueiredo_M.pdf: 1776163 bytes, checksum: 25832a16e6e32e0da542e7591cac5bdd (MD5) Previous issue date: 2013 / Resumo: A Doença de Crohn (DC) é caracterizada por uma inflamação crônica que pode afetar qualquer parte do trato digestivo. Na fase aguda, os sintomas gastrointestinais podem levar à desnutrição. Na remissão da doença, alguns pacientes podem apresentar sobrepeso ou obesidade, o que contribui para aumentar a produção de citocinas pró-inflamatórias pelo tecido adiposo. Com o objetivo de avaliar os efeitos de dois suplementos nutricionais sobre o estado nutricional de pacientes com DC, foi realizado um ensaio clínico, randomizado, duplo-cego, paralelo com dois braços. Os participantes receberam suplemento com proteínas do soro de leite (PSL) ou suplemento com proteínas de soja (PS), durante 16 semanas. A avaliação nutricional foi feita por meio de medidas antropométricas, bioimpedância, recordatório alimentar de 24 horas e dosagens de albumina e pré-albumina. Para a avaliação da atividade da doença foram utilizados o Índice de Atividade da Doença de Crohn (IADC) e a dosagem de proteína C reativa (PCR). Na primeira avaliação (n=68), 93% dos pacientes estavam em remissão da doença (IACD<150), 36% apresentaram sobrepeso ou obesidade e apenas 5% estavam desnutridos. Com relação à ingestão alimentar, mais de 50% dos pacientes tinha um consumo inadequado de cálcio, potássio, e vitaminas A, C e D. Pacientes que estavam sob terapia com anti-TNF-? apresentaram Índice de Massa Corporal (IMC), percentual de gordura corporal (%GC) e prega cutânea tricipital (PCT) maiores do que aqueles sob terapia com, apenas, azatioprina. As 16 semanas de suplementação foram concluídas por 19 pacientes no grupo com PSL e 22 no grupo PS. Os suplementos não tiveram efeitos no IADC e PCR, porém modificaram a composição corporal. Houve aumento da circunferência muscular do braço (CMB), área muscular do braço corrigida (AMBc) e percentual de massa magra (%MM), e redução da PCT e do %GC, nos dois grupos. O sobrepeso, a obesidade e a ingestão inadequada de micronutrientes foram alterações nutricionais observadas em alguns pacientes com DC deste estudo, e indicam a necessidade de orientações dietéticas para corrigi-las. Os suplementos nutricionais com PSL e PS, após 16 semanas de uso, reduziram a gordura corporal dos pacientes, e poderiam ser utilizados como estratégia para tratar a obesidade. Além disso, a inflamação decorrente do excesso de tecido adiposo poderia ser prevenida, contribuindo para uma melhor evolução clínica / Abstract: Crohn's Disease (CD) is characterized by a chronic inflammation that affects any part of the gastrointestinal tract. In the acute phase, gastrointestinal symptoms may lead to malnutrition. During disease remission, some patients are overweight or obese; as adipose tissue produces proinflammatory cytokines, its excess may aggravate inflammation. To evaluate the effects of two supplements on nutritional status in CD patients, we performed a prospective, randomized, double-blind, parallel-arm trial. Participants received whey protein (WP) or soy protein (SP) supplement for 16 weeks. Nutritional assessment was performed by anthropometric measurements, bioelectrical impedance, 24-hour dietary recall, serum albumin and pre-albumin. The Crohn's Disease Activity Index (CDAI) and serum C-reactive protein (CRP) were used for the assessment of the disease activity. In the first evaluation (n = 68), 93% of the patients were in clinical remission (CDAI <150), 36% were overweight or obese and only 5% were malnourished. Over 50% of the patients had an inadequate intake of calcium, potassium, and vitamins A, C and D. Patients under treatment with anti-TNF- alpha had body mass index (BMI), body fat percentage (%BF) and triciptal skin fold (TSF) greater than those undergoing azathioprine therapy. Nineteen patients in the WP group and twenty-two in the SP group completed the 16 weeks of supplementation. The supplements had no effect on CDAI and CRP, but contributed to body composition change. The TSF and %BF decreased, whereas mid-arm muscle circumference (MAMC), corrected arm muscle area (CAMA) and body lean percentage (%BL) increased, in the two groups. Some patients in this study presented overweight, obesity or low intake of micronutrients, dietary advice is needed to correct these nutritional abnormalities. The supplementation with WP and SP may contribute to the reduction of overweight and obesity through reducing body fat and thus contributing to inflammatory control, preventing disease progression / Mestrado / Saude da Criança e do Adolescente / Mestra em Saúde da Criança e do Adolescente

Les maladies inflammatoires chroniques de l’intestin font partie des pathologies immunitaires. Leur pathogenèse est directement liée à une réponse immune exagérée dirigée contre des bactéries commensales normalement présentes dans l’intestin, chez des individus génétiquement prédisposés. Parmi les facteurs favorisants, on trouve l’amélioration du niveau d’hygiène ainsi qu’une diminution des infections parasitaires. Des études épidémiologiques ont suggéré une relation entre la prévalence des infections par les helminthes et l’incidence des maladies inflammatoires chroniques de l’intestin dans les pays en développement. Ces infections parasitaires induisant une réponse immune de type Th2, il est donc proposé qu’elles participent la régulation des maladies inflammatoires médiées par une réponse immune de type Th1, comme la maladie de Crohn.Notre équipe s’est intéressée à l’effet immuno-modulateur d’une protéine du Schistosome, la P28GST (Glutathion S-transferase) dont les propriétés immunogénétiques pro-Th2 ont été démontrées précédemment dans des modèles expérimentaux et chez l’homme. Au cours de notre travail, nous avons montré que l’immunisation avec la P28GST était capable de diminuer de manière façon significative la colite expérimentale dans deux modèles animaux. L’immunisation avec cette enzyme parasitaire, produite sous forme recombinante, a réduit les scores cliniques et histologiques obtenus après induction de colite expérimentale par injection de l’haptène TNBS chez des rats Sprague Dawley rats ainsi que chez des souris C57Bl/6. Cet effet est associé à une diminution des marqueurs de l’inflammation (Myéloperoxidase) et de lexpression de l’ARN messager codant pour des cytokines pro-inflammatoires (IL-1&#946;, IL-17 et TNF) dans le colon des animaux. Nous détectons une modulation de la réponse immune caractérisée par une diminution du profil Th1 mesuré par la présence d’ARN messager codant pour l’IFN&#947; vers un profil de type Th2, associé à une augmentation de l’ARN messager codant pour l’IL-4, l’IL-5 et l’IL-13. L’augmentation du rapport ARN messager Arg1/iNOS2 ainsi que la détection de cellules Arginase positives par immuno-histo chimie dans le colon des animaux immunisés suggèrent la présence de macrophages alternatifs (AAM), dont on connait le rôle anti-inflammatoire et l’association à une réponse de type Th2. Des résultats similaires ont été obtenus dans un autre modèle expérimental, chez la souris.Nous avons comparé l’effet de cette protéine du Schistosome avec l’effet de l’infection par des larves du parasite grâce à deux modèles d’infection : soit une infection au long cours (associé avec une réponse immune de type Th2), soit une infection récente (avec une réponse immune de type Th1). Nos résultats montrent que l’immunisation par une seule protéine de schistosome, la P28GST, réduit l’inflammation intestinale aussi bien que l’infection au long cours, tandis que les animaux récemment infectés n’étaient pas protégés de la colite. En conclusion, notre étude présente les premières évidences que l’immunisation avec une protéine recombinante de Schistosome pourrait réduire de manière préventive la colite expérimentale induite par l’injection d’une haptène dans deux modèles de rongeurs. Si les mécanismes d’action précis doivent encore être élucidés, nos travaux suggèrent que l’effet anti-inflammatoire de la P28 GST puisse avoir des applications dans la prévention de l’inflammation intestinale permettant d’envisager une utilisation chez l’homme, notamment dans la prévention des rechutes de la maladie de Crohn. / Inflammatory bowel diseases are considered part of immune-mediated inflammatory disorders. Their pathogenesis was linked to an inappropriate exaggerated immune response to commensal bacteria normally present in the bowel, in genetically predisposed individuals. Increase of the level of hygiene and decrease exposure to helminthic infections was suggested as predisposing factors to IBD. Epidemiologic data have given a clue on the relation of prevalence of helminthic infections and the incidence of inflammatory bowel diseases in developing countries. The Th2 polarized T cell response driven by helminthic infection has been linked to the attenuation of Th1 driven inflammatory responses, preventing some Th1 mediated autoimmune diseases in their host, including Crohn’s disease.Our work focused on the immuno-modulatory effect of a Schistosome protein – P28GST (a Glutathion S-transferase). Its immuno-genetique, pro-Th2, characters have been previously demonstrated in experimental models as well as clinical trials. We showed that immunization with P28GST was able to significantly reduce experimentally induced colitis in two animal models.Immunisation with this recombinant parasitic enzyme reduced clinical and histological scores of the TNBS induced colitis in both Sprague Dawley rats as well as in C57Bl/6 mice. This effect was associated with a decrease in the expression of inflammatory markers (Myeloperoxidase) as well as mRNA expression of pro-inflammatory cytokines (IL-1&#946;, IL-17 and TNF) in the colon of sacrificed animals. We detected a shift of the immune response characterized with decrease of Th1 immune response assessed by the mRNA expression of IFN&#947; towards a less pathological Th2 immune response assessed by the mRNA expression of IL-4, IL-5 and IL-13. An increase in the ratio of mRNA expression of Arg1/iNOS2, as well as the immuno-histochemical detection of Arginase positive cells in the colon of the sacrificed animals suggested the presence of alternatively activated macrophages (AAMs) characterized by their anti-inflammatory effect and their association with the Th2 immune response. Similar results have been obtained in another animal model, the C57Bl/6 mice.We have also compared the effect of a single recombinant Schistosome protein to two models of infection with living schistosome parasites, either with long standing infection (associated with a Th2-type response) or with a recent onset exposure (a Th1-type response). Our results showed that immunisation with a single Schistosome protein, the P28GST; give similar results to established infection in term of reduction of intestinal inflammation, whereas recently infected rats were not protected against colitis.In conclusion, this study provides the first evidence that immunization with a recombinant protein from the Schistosome helminth parasite prevents hapten-induced colitis in two models of rodents. Although further studies are needed to illustrate the exact mechanisms of action implicated in the immuno-modulatory effect, P28GST is a promising molecule exerting a potent anti-inflammatory role in the prevention of colitis. The potential effect of this helminthic enzyme is actually taken in consideration in the prevention of Crohn’s disease relapses in humans.

Pathologie multifactorielle, la maladie de Crohn pourrait être la conséquence de facteurs environnementaux, génétiques et impliquerait également une dérégulation de la réponse immunitaire vis-à-vis du microbiote intestinal. En effet, des variations qualitatives et quantitatives du microbiote intestinal ont pu être mises en évidence chez les patients atteints de cette pathologie. Dysbiose également observée dans le cancer colorectal dont le risque de développement est doublé chez les patients atteints de maladie de Crohn.Dans cette étude, nous nous sommes intéressés au rôle du récepteur de l’immunité innée NOD2, dont les polymorphismes génétiques prédisposent à la maladie de Crohn ainsi qu’à l’influence du microbiote intestinal dans l’établissement de colites et du cancer colorectal.Un modèle murin de colite chimique et de cancer associé à la colite (CAC) a permis de mettre en évidence une aggravation des signes cliniques de ces pathologies chez les animaux Nod2-/- et Rip2-/- en comparaison aux animaux sauvages suggérant un rôle protecteur de NOD2 et de son adaptateur protéique RIP2 dans la colite et à plus long terme dans la tumorigenèse.En vue de déterminer l’origine de ce sur-risque observé chez les animaux Nod2 ou Rip2-déficients nous avons tout d’abord vérifié le caractère transmissible de la colite. Des expériences de co-hébergement et d’adoption ont montré une transmission de la susceptibilité associée aux animaux déficients à des animaux sauvages de manière horizontale (par les congénères) et verticale (par la mère). Une analyse systématique du microbiote dans le modèle de CAC a mis en évidence une réduction de la diversité microbienne ainsi qu’une dysbiose chez les animaux Nod2-/- suggérant une implication de la flore dans l’établissement du sur-risque observé chez les animaux déficients. L’administration d’une antibiothérapie à large spectre a conforté cette hypothèse en réduisant la susceptibilité des animaux Nod2-/-. Une analyse transcriptionnelle a été réalisée afin d’établir les mécanismes moléculaires associés à la colite en réponse au microbiote et a permis de mettre en cause l’IL-6 ainsi que ses gènes cibles déjà décrits pour leur caractère pro-tumoral. Implication confirmée par inhibition de la voie IL-6 à l’aide d’un anticorps bloquant son récepteur capable de réduire la tumorigenèse. Enfin, la génération de souris axéniques Nod2-/- et leur recolonisation par une flore issue de souris sauvages a montré la possibilité d’inverser le sur-risque observé chez les Nod2-/-.Pour conclure, dans un contexte déficient pour Nod2, une réponse inflammatoire à l’encontre du microbiote intestinal dépendante de l’IL-6 favoriserait la mise en place d’une flore délétère qui prédisposerait à la colite et au CAC. Le caractère transmissible de cette flore représente en soi un outil pour l’étude des interactions avec le système immunitaire inné et adaptatif. Enfin, la mise en évidence de la ou des bactéries colitogènes ainsi que des mécanismes inflammatoires impliqués, permettra la mise au point de thérapies ciblées en vue de réduire la tumorigenèse associée à une inflammation persistante chez les patients atteints de la maladie de Crohn. / Crohn's disease is a multifactorial disease that could result from environmental factors, genetic factors and would also involved a dysregulation of the immune response against the intestinal microbiota. Indeed, qualitative and quantitative variations of the gut microbiota could be detected in Crohn’s patients or colorectal cancers patients. Moreover, risk of colorectal cancer development is two-fold increased in patients with Croh's disease.In this study, we focused on the role of innate immunity receptor Nod2, which polymorphisms predispose to Crohn's disease, and the influence of gut microbiota in the development of colitis and colorectal cancer.A chemical colitis model and chemical colitis associated cancer (CAC) in mouse highlighted an increased susceptibility of Nod2-/- and Rip2-/- animals compared to WT animals suggesting that NOD2 and its adaptor protein RIP2 can protect from colitis and tumorigenesis.To determine the origin of this increased risk observed in Nod2 or RIP2-deficient animals we first checked the transmissibility of colitis. Co-housing and cross-fostering experiments showed a transmission of susceptibility associated with deficient animals in WT animals horizontally (by congeners) and vertically (by mother). A systematic analysis of the microbiota in CAC model showed a reduction of microbial diversity and a dysbiosis in Nod2-/- animals suggesting an involvement of the flora in the establishment of the increased risk observed in deficient animals. Administration of a broad-spectrum antibiotherapy has confirmed this hypothesis by reducing the susceptibility of Nod2-/- animals. A transcriptional analysis was performed to determine the molecular mechanisms associated with colitis in response to microbiota and highlighted IL-6 and its target genes already described for theirs pro-tumoral effects. Involvement of IL-6 was confirmed by inhibition of IL-6 using an antibody blocking IL-6 receptor that can reduced tumorigenesis. Finally, the generation of germ free Nod2-deficient mice and recolonization by WT mice microbiota showed the ability to reverse the increased risk observed in Nod2-/- mice.Finally, in a context Nod2-deficient, an IL-6-dependent inflammatory response directed against intestinal microbiota, promote the establishment of pro-colitogenic microbiota and would predisposed to colitis and CAC. The transmissibility of this flora may be itself a tool to study interactions between innate and adaptive immune systems. Finally, identification of colitogenic bacteria and inflammatory mechanisms involved, will allow the development of therapies in order to reduce tumorigenesis associated with persistent inflammation in patients with Crohn disease.

Submitted by Reginaldo Soares de Freitas (reginaldo.freitas@ufv.br) on 2015-11-18T13:53:39Z No. of bitstreams: 1 texto completo.pdf: 1408584 bytes, checksum: 93c92bfb4c0654bc0272f8ef82b674ea (MD5) / Made available in DSpace on 2015-11-18T13:53:39Z (GMT). No. of bitstreams: 1 texto completo.pdf: 1408584 bytes, checksum: 93c92bfb4c0654bc0272f8ef82b674ea (MD5) Previous issue date: 2015-02-20 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Mycobacterium avium ssp. paratuberculosis (MAP) é o agente etiológico da doença de Johne ou paratuberculose, enterite granulomatosa crônica caracterizada por diarreia persistente e perda de peso progressiva que acomete ruminantes. Pode também ser isolado a partir de amostras intestinais de pacientes humanos, com doenças intestinais, principalmente portadores da doença de Crohn. Essa é uma doença de etiologia desconhecida, que se caracteriza por inflamação crônica, focal, assimétrica transmural e ocasionalmente granuloma- tosa, que pode acometer qualquer segmento do tubo digestivo. O isolamento de MAP e as semelhanças entre os processos clínicos e histopatológicos da paratuberculose e da doença de Crohn são algumas das razões pelas quais se investiga o potencial zoonótico da bactéria. As principais vias de eliminação do agente são através do leite e das fezes que contaminam os pastos e, direta ou indiretamente os cursos d’agua podendo dessa forma infectar humanos pela ingestão de água contendo o micro-organismo viável. MAP é uma bactéria resistente e responsável por grandes prejuízos econômicos e produtivos, sendo demonstrada sua sobrevivência no ambiente por longos períodos, além da resistência a pasteurização e à agentes de desinfecção aplicados ao tratamento da água para consumo humano. Diante disso, o estudo teve como objetivos: - identificar fatores de risco envolvidos com a presença de MAP em amostras de intestino humano, através da aplicação de questionário, em conjunto com da- dos prévios sobre a presença da bactéria em amostras de biópsias intestinais de pacientes portadores de Doença de Crohn, retocolite ulcerativa e portadores de doenças intestinais não inflamatórias, -verificar a presença do agente na água para consumo humano e animal através de PCR convencional e do cultivo microbiológico de amostras coletados em 10 propriedades de caprinocultura leiteira da Zona da Mata Mineira e realizar uma revisão bibliográfica dos estudos sobre a paratuberculose na América Latina. Quanto às amostras de água, MAP foi identificado viável em quatro (40%) das amostras de consumo animal, e identificado por PCR em três (30%) das de consumo humano além de uma quinta amostra de consumo animal (10%). Esse resultado demonstra o papel da água como reservatório do agente, mantendo o ciclo de infecção ativo e servindo de amostra confiável para o diagnóstico da presença do agente no rebanho já que, aparentemente não está condicionada a eliminação intermitente, como ocorre com as fezes desses animais. Nesse estudo também puderam ser identificados fatores de risco para a ocorrência do agente na água e em biópsias intestinais humanas, como o consumo de leite e derivados informais, assim como histórico familiar de agravos intestinais. Na América Latina MAP foi pesquisado em 10 países e identificado em nove, infectando, bovinos, caprinos e animais silvestres. Os resultados desse estudo contribuem para a identificação de fatores de risco envolvidos na transmissão de MAP para humanos, permitindo a sugestão de medidas que previnam ou reduzam a exposição ao agente. Esses fatores de risco identificados também demonstram a importância do leite na veiculação do agente por leite e produtos lácteos, com destaque para aqueles que não passaram pela pasteurização. Além disso, os estudos sobre água auxiliaram a elucidação do papel da ingestão da água na transmissão do agente, que não é pesquisado na rotina de tratamento, indicando exposição ao agente para humanos pode ser dar através do consumo de água contaminada por fezes de animais com paratuberculose. Esse estudo foi o primeiro sobre o agente na água no Brasil, e um dos poucos no mundo. / Mycobacterium avium ssp. paratuberculosis (MAP) is the etiologic agent of Johne's disease or paratuberculosis, a chronic granulomatous enteritis characterized by persistent diarrhea and progressive weight loss that may affects ruminants. MAP is also be isolated from intestinal samples from human patients with intestinal diseases, particularly Crohn's disease patients. This is a disease of unknown etiology that is characterized by chronic inflammation, focal, transmural asymmetric and occasionally granulomatous lesions, which can affect any segment of the digestive tract. The isolation of MAP and the similarities between the clinical and pathologic processes of paratuberculosis and Crohn's disease are some of the reasons for investigating the zoonotic potential of bacteria. The main agent’s disposal routes are through feces and milk that contaminate pastures and directly or indirectly the watercourses and can thus infect humans by drinking water containing viable microorganism. MAP is a resistant bacteria and responsible for significant economic and productive loss, and demonstrated its survival in the environment for long periods, in addition to the resistance to pasteurization and disinfection agents applied to water treatment for human consumption. Thus, the study aimed to: - identify risk factors involved with the presence of MAP in human gut samples, through the questionnaire, together with previous data on the presence of bacteria in samples of intestinal biopsies of patients Crohn's disease, ulcerative colitis and patients with non- inflammatory intestinal diseases, -check the agent's presence in the water for human and animal consumption by conventional PCR and microbiological culture samples collected in 10 properties of dairy goat of the Zona da Mata Mineira and,- conduct a literature review of the studies on paratuberculosis in Latin America. As for the water samples, MAP was identified feasible in four (40%) of the samples of animal feed, and identified by PCR in three (30%) of human consumption as well as a fifth sample of animal consumption (10%). This result demonstrates the role of water as an agent of the reservoir, keeping the active infection cycle and serving as a reliable sample for the diagnosis of the agent's presence in the herd since apparently is not subject to intermittent shedding, as with the feces of these animals. In this study could also be identified risk factors for the occurrence of the agent in in human intestinal biopsies, as the consumption of unpasteurized milk and informal derivatives as well as family history of bowel diseases. In Latin America MAP was investigated in 10 countries and identified in nine, infecting, cattle, goats and wild animals. The results of this study contribute to the identification of risk factors involved in the MAP transmission to humans, allowing the suggestion of measures to prevent or reduce exposure. These identified risk factors also demonstrate the importance of milk in placement agent for milk and milk products, especially those who have not gone through the pasteurization. Furthermore, studies on water helped to elucidate the role of water ingestion in the transmission of the agent, which is not searched in routine treatment, indicating exposure to the agent for humans can occur through the consumption of water contaminated by faeces of animals carrying paratuberculosis. This study was the first about the agent in water in Brazil, and one of the few in the world.

Orientador: Alba Regina Monteiro Souza Brito / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-26T17:16:46Z (GMT). No. of bitstreams: 1 Almeida_AnaCristinaAlvesde_D.pdf: 2447485 bytes, checksum: 029d5569d7c4d1eaaffa8f4a530937dd (MD5) Previous issue date: 2015 / Resumo: A Doença Inflamatória Intestinal (DII), que compreende a Doença de Crohn (DC) e a Retocolite Ulcerativa (RCU), é marcada por resposta inflamatória exacerbada a componentes da microbiota, com danos à mucosa do cólon. O tratamento de DII envolve drogas ineficazes para a remissão de todos os parâmetros da doença, com vários efeitos colaterais e custo elevado, o que motiva a busca de novos agentes terapêuticos. Sendo os produtos naturais uma importante fonte para desenvolvimento de medicamentos, buscou-se, nesse trabalho, avaliar o efeito do alcaloide índigo em modelos experimentais de colite. Inicialmente, foi avaliado o tratamento oral com índigo em colite aguda induzida por ácido trinitrobenzeno sulfônico (TNBS) em ratos HanUnib: WH (Wistar), um modelo experimental de DC. O tratamento com índigo resultou em redução da lesão macroscópica, medida através de escore, na dose de 3 mg/kg, e da área de lesão ulcerativa (doses 0,1; 3; 10 e 30 mg/kg). Apenas a administração da maior dose (30 mg/kg) evitou o aumento da razão peso/comprimento do cólon e não houve diminuição da diarreia e aderência do cólon, após tratamento com o alcaloide. Danos histológicos foram minimizados no cólon de animais tratados com índigo (3, 6 e 12 mg/kg). Como a lesão macroscópica por TNBS é bastante severa, a dose de 3 mg/kg, que reduziu tanto o índice (escore) quanto a área de lesão, foi selecionada para as análises posteriores. Nos ratos tratados com índigo (3 mg/kg), houve aumento na atividade da superóxido dismutase (SOD) e redução da atividade da glutationa peroxidase (GPx), redução dos níveis de peroxidação lipídica (LPO) e, parcialmente, de glutationa (GSH), sem alteração significativa na atividade da glutationa redutase (GR) e catalase (CAT). O tratamento com índigo (3 mg/kg) evitou aumento da expressão de ciclooxigenase 2 (COX-2), e não mostrou efeito significativo na expressão de fator nuclear de transcrição ?B (NF-?B) e na concentração de citocina anti-inflamatória interleucina 10 (IL-10). O segundo modelo experimental empregado neste trabalho foi a indução de colite aguda por dextrana sal sódico (DSS), em camundongos Unib: SW (Swiss), que apresenta similaridades com a RCU. A administração de índigo (3 mg/kg) não levou à redução significativa do índice de atividade da doença (DAI), o qual engloba alteração de peso corporal, presença de diarreia e sangue nas fezes; entretanto, foi eficaz em evitar o aumento da razão peso/comprimento do cólon. Em análise histológica, notou-se menor gravidade dos danos causados pelo DSS (aumento da parede do cólon, com infiltração celular na mucosa e submucosa, desorganização do epitélio). No cólon de animais tratados com índigo, observou-se aumento na atividade da SOD, não acompanhada de mudanças nos níveis de GSH e atividade da GPx, GR e CAT. O alcaloide inibiu aumento na concentração cólica da citocina IL-6, mas não da interleucina IL-1?. Em modelo experimental de colite crônica, com recidiva, associada a câncer de cólon por azoximetano e DSS (AOM/DSS) em camundongos Unib: SW (Swiss) machos, a administração de índigo reduziu a mortalidade, minimizou a perda de massa corporal dos animais e evitou o aumento da razão peso/comprimento do cólon. A substância teste, entretanto, não foi capaz de reduzir o DAI, nesse experimento, por não minimizar a perda de consistência e o aparecimento de sangue nas fezes. No modelo de colite crônica por AOM/DSS (9 semanas), animais sadios tratados com salina fisiológica (veículo) ou índigo (3 mg/kg) foram monitorados para análise de sinais de toxicidade do alcaloide, a partir dos parâmetros: mortalidade, evolução de peso corporal, consumo de ração, peso e avaliação macroscópica dos órgãos coração, pulmões, rins e fígado. Não foram encontrados indícios de toxicidade nos parâmetros avaliados, mas devido à mortalidade de 17 % dos camundongos tratados com índigo, foi realizado teste de toxicidade aguda de dose única. Após 14 dias da administração oral e intraperitoneal de índigo (1000 mg/kg), em camundongos Unib:SW (Swiss) machos e fêmeas, não foram observadas alterações na evolução de peso corporal, consumo de água e ração, peso de órgãos vitais, comportamento e sobrevivência dos animais. Em suma, o alcaloide índigo apresentou efeito anti-inflamatório em modelos de colite por TNBS, DSS e AOM/DSS. A redução do estresse oxidativo deve ter papel central na redução das lesões causadas pelo TNBS, enquanto que na colite por DSS, a regulação da IL-6 parece ser determinante para redução dos danos. Apesar de não minimizar todos os parâmetros de danos causados pela colite, o tratamento com índigo possibilitou que os animais ficassem, em geral, menos debilitados (evidenciado pelo maior peso e consumo de ração) que os animais não tratados / Abstract: Inflammatory Bowel diseases (IBD) are known as na exacerbated imune response within the intestinal tract, mainly the mucosa of the colon. The IBD treatment is rather ineffective, including various side effects and high costs. Thus, the research with active compounds may bring therapeutic alternatives for IBD. Since natural products have been a vast source for pharmacology, we decided to investigate the effect of Indigo alkaloid in experimental models of IBD. The oral administration of Indigo (3 mg/Kg) in trinitrobenzenesulphonic acid (TNBS) -induced colitis showed beneficial results in the macroscopic and microscopic lesions, without significant results in the other evaluated parameters (diarrhea and intestine adhesion). We observed a reduction in the sulfhydryl groups (GSH) and in the activity of Glutathione peroxidase (GPx), an increase in the activity of Superoxide Dismutase (SOD) and Lipid Peroxidation (LPO). The treatment with Indigo (3 mg/Kg) prevented an increase in the LPO levels, and partially, the reduction of GSH levels. Furthermore, Indigo inhibited the increase of Cycloxigenase 2 (COX-2) expression. In the Indigo-treated animals, the expression of the Nuclear Factor kB (NF-kB) and the concentration of interleukin 10 (IL-10) were kept at intermediary levels between the healthy group and the non-treated colitic group (Veículo + TNBS). In the Dextran Sodium Salt (DSS), Indigo showed no effect on the disease associated index (DAI), which includes body weight reduction, consistence and blood in feces. However, the 7-day oral treatment with Indigo was capable of avoiding the weight/length ratio of the colon, which is usually augmented in the intestinal inflammation. In the histological, we observed a thickening of the intestinal wall, with mucosal and submucosal cell infiltration, necrotic areas as well as epithelium disorganization in the DSS-induced inflammation. The treatment with Indigo showed less severe morphological lesions. In the Dss-induced colitis, IL-6 and IL-1? levels were higher in the negative control group (DSS), which was prevented with the treatment with Indigo. In the azoximethane/DSS-cancer associated recidive model of colitis, the administration of Indigo lowered the death rate, minimized the body weight loss and also prevented the increase in the wejght/length ratio of the colon. The test substance, however, was not capable of of reducing DAI in this model, since it didn't minimize the loss of consistence and neither the blood in feces. Animals treated with saline or Indigo for 9 weeks were used for the analyses of Indigo toxicity through the following parameters: body weight evolution, chaw consumption, organ weight and macroscopic evaluation (heart, kidneys, lung and liver). In this analysis, no signs of toxicity were found for this dose of Indigo. Although it did not enhance all the parameters studied in this model of colitis, we observed that the Indigo-treated animals were, in general, less debilitated than the non-treated ones. Other studies and parameters have to be performed for a better understanding of the alkaloid effects in the intestinal inflammation / Doutorado / Fármacos, Medicamentos e Insumos para Saúde / Doutora em Ciências

Le gène NOD2, impliqué dans les réponses immunitaires innées contre le peptidoglycane bactérien, est étroitement associé à la maladie de Crohn (MC) avec des Odd Ratio(OR) allant de 3 à 36 selon le génotype et a été initialement identifié par des analyses de liaisons génétiques. Les données des familles multiplexes (familles définies par la présence de trois ou plus de trois apparentés au premier degré atteints de MC) issues du registre EPIMAD ont été analysées. Il a été précédemment rapporté que dans les 22 familles multiplexes EPIMAD génotypées pour les 3 mutations majeures du gène NOD2une fréquence élevée de ces mutations du gène NOD2 : R702W, G908R et L1007fs, pouvait expliquer la fréquence élevée de MC dans ces familles. Cependant, quelques familles multiplexes EPIMAD ne présentaient aucune de ces mutations R702W, G908R et L1007fs.Afin d’identifier de nouvelles variations génétiques ayant un effet majeur dans la MC, un protocole de Whole Exome Séquencing (WES) a été effectué sur l’une de ces familles multiplexes EPIMAD (F49M) présentant quatre sujets atteints de MC sur deux générations.Une variation rare du gène NOD2, N1010K, s’est avérée présente chez tous les patients atteints et absente chez tous les sujets contrôles intrafamiliaux . L’évaluation in silico et la modélisation 3D ont mis en évidence un effet délétère hautement probable de la mutation de N1010K suggérant donc fortement qu’elle pourrait être un nouveau facteur de risque majeur impliqué dans la susceptibilité génétique à la maladie de Crohn. Elle pourrait expliquer l’agrégation familiale de la MC dans la famille analysée. La présence d’une maladie plus sévère chez les patients hétérozygotes composites N1010K/L1007fs plaide en faveur de l’effet délétère de la mutation N1010K.En plus de la caractérisation d’une nouvelle mutation rare du gène NOD2, 2 autres variants potentiels ont été identifiés : les mutations D359H et G33V respectivement des gènes BPIFB2 et DEFB132. Les protéines codées par ces gènes sont impliquées dans les mêmes voies de signalisation : la voie de signalisation des défensines ainsi que dans celle du système immunitaire inné. L’évaluation in silico des effet de ces mutations a mis en évidence un effet délétère hautement probable pour D359H et G33V des gènes BPIFB2et DEFB132. Ainsi, on peut supposer que bien que les deux mutations D359H du gèneBPIFB2 et G33V du gène DEFB132, soient localisés sur deux gènes différents impliquées dans les mêmes voies de signalisation, elles pourraient agir ensemble et conduire à un effet dysfonctionnel cumulatif impliqué également dans l’agrégation familiale de la MC dans la famille F49M.Ainsi, Pour la famille F49M, l’agrégation familiale pourrait reposer sur l’accumulation de plusieurs mutations à effet délétère (N1010K, D359H et G33V). / The NOD2 gene, involved in innate immune responses, has been found to be highlyassociated with Crohn’s Disease (CD). EPIMAD multiplex families with three or more CDaffectedmembers were previously reported to be related to a high frequency of NOD2gene mutations : R702W, G908R, and L1007fs. However, some rare EPIMAD CD multiplexfamilies were described without any of the common NOD2 linked-to-disease mutations.In order to identify new genetic variation(s) with amajor effect in CD, whole exomesequencing was performed on available subjects in a multiplex family (F49M), withoutknown common NOD2 mutations and comprising four patients affected with Crohn’s diseaseand three unaffected related subjects on two generations . A rare and, not yet, reportedmissense mutation of the NOD2 gene, N1010K, was detected and co-segregated acrossaffected patients (present in allmembers affectedwith CD and absent in all unaffected familialcontrol subjects). In silico evaluation of the deleterious effect of the mutation and3D modelling highlighted evidences for an adverse effect of the N1010K mutation withregard to the function of the NOD2 protein and the genetic risk of CD.Moreover, N1010Kand L1007fs as a compound heterozygous state in two, more severe CD family membersstrongly suggests that N1010K could be a new risk factor involved in Crohn’s disease geneticsusceptibility.In addition to the characterization of a new rare mutation of the NOD2 gene, 2 otherpotential variants have been identified : the D359H and G33V mutations, respectively, inthe BPIFB2 and DEFB132 genes. The proteins encoded by these genes are involved in thesame pathways : the pathway of defensins and the pathway of the innate immune system.In silico evaluation of the deleterious effect of mutations revealed a potential deleteriouseffect of D359H and G33V mutations. Thus, we could hypothesize that although the two mutations D359H and G33V are located on two different genes but involved in the same signaling pathways, they could act together and determine a cumulative dysfunctional effect also involved as determinants of the familial aggregation of Crohn’s disease in family F49M.Thus, for the F49M family, familial aggregation could be based on the accumulation of several deleterious mutations (N1010K, D359H and G33V).

No description available.

Bakgrund: Inflammatorisk tarmsjukdom (IBD) är ett samlingsnamn för de kroniska tarmsjukdomarna Crohns sjukdom (CD) och Ulcerös kolit (UK). Det gemensamma för de två sjukdomarna är att de löper i skov med försämringsperioder och långa besvärsfria perioder samt att de drabbar relativt unga personer. Det är viktigt att sjuksköterskan kan stödja dessa individer genom evidensbaserad och personcentrerad vård för att kunna ge en så god omvårdnad som möjligt.  Syfte: Beskriva individers upplevelse av att leva med inflammatorisk tarmsjukdom Metod: En litteraturöversikt valdes som metod. Artikelsökningen genomfördes i databaserna CINAHL Complete och PubMed. De begränsningar som gjordes i databassökningarna var vetenskapliga originalartiklar, skrivna på engelska, genomgått peer-review och publicerade mellan 2009-2019. Totalt inkluderades elva artiklar i resultatet, av dessa var tio artiklar kvalitativa och en var kvantitativ. Resultat: Resultatet visade att individerna upplevde att sjukdomen påverkade deras arbetsliv, sociala liv, känslor och identitet. Deras möte med hälso- och sjukvården påverkade personernas förtroende för vården samt deras vilja att söka vård framöver. Det visades även att personer med inflammatorisk tarmsjukdom genomgick en transitionsperiod efter deras diagnos. Hur personerna upplevde att leva med IBD påverkades av om de för tillfället befann sig i ett skov eller nyligen fått diagnosen. De personer som befann sig i ett skov eller nyligen fått diagnosen hade en övervägande negativ syn.  Diskussion: Resultatet diskuterades utifrån Katie Erikssons teori om lidande och hälsa. Författarna resonerade om individernas negativa påverkan kunde kopplas till stigman av sjukdomen. De diskuterade även angående den långsiktiga påverkan av frånvaron från arbetet och sociala sammanhang. Författarna fann i resultatet att individer med IBD upplevde sjukdomen olika i sin vardag beroende på hur länge de haft sjukdomen och vilken inställning de har gentemot sin IBD. Därmed bör vården anpassas efter de individuella behoven för att säkerställa att insatserna främjar hälsan. / Background: Inflammatory bowel disease (IBD) is a chronic illness that includes Crohn´s disease (CD) and ulcerative colitis (UK). Both diseases have in common that they have relapse and periods with improvement. The diseases effects relatively young people. It is important that the nurse can support these individuals through evidence based and person-centred care in order to provide the best possible care. Aim: Describe individuals experiences of living with inflammatory bowel disease  Method: A literature review was chosen as the method. The article search was carried out in the databases CINAHL complete and PubMed. The limitations made in the database searches were scientific original articles, written in English, peer-reviewed and published over the last ten years. A total of eleven articles was included in the result, of which ten were of qualitative design and one was quantitative design. Results: The results showed that the individuals experienced that the disease affected their working life, social life, feelings and identity. Their meeting with healthcare services affected their trust in the care and their willingness to seek care in the future. It was also shown that people with inflammatory bowel disease underwent a transition period after the diagnosis. How the individuals experienced living with IBD was affected by whether they were relapsing or in remission. People currently in a relapse had a more negative view of the disease.  Discussion: The result was discussed based on Katie Eriksson´s theory of suffering and health. The authors reasoned if the negative impact of the individuals could be linked to the stigma and shame of the disease. They also discussed the long-term impact of the absence from work and social activities. The authors found in the results that individuals with IBD experienced the disease differently in their daily lives depending on how long they had the disease and what attitude they had towards their IBD. The care should be adapted to the individual needs to ensure that the efforts promotes health.